WallStSmart

Boston Scientific Corp (BSX)vsWalt Disney Company (DIS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Walt Disney Company generates 377% more annual revenue ($95.72B vs $20.07B). BSX leads profitability with a 14.4% profit margin vs 12.8%. BSX appears more attractively valued with a PEG of 0.75. BSX earns a higher WallStSmart Score of 63/100 (C+).

BSX

Buy

63

out of 100

Grade: C+

Growth: 8.0Profit: 6.5Value: 8.7Quality: 5.5
Piotroski: 4/9

DIS

Buy

59

out of 100

Grade: C

Growth: 4.0Profit: 6.5Value: 4.7Quality: 6.5
Piotroski: 6/9Altman Z: 1.91
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BSXUndervalued (+1.2%)

Margin of Safety

+1.2%

Fair Value

$70.62

Current Price

$69.78

$0.84 discount

UndervaluedFair: $70.62Overvalued
DISSignificantly Overvalued (-129.7%)

Margin of Safety

-129.7%

Fair Value

$46.17

Current Price

$95.95

$49.78 premium

UndervaluedFair: $46.17Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BSX4 strengths · Avg: 8.3/10
Market CapQuality
$101.28B9/10

Large-cap with strong market position

PEG RatioValuation
0.758/10

Growing faster than its price suggests

Revenue GrowthGrowth
15.9%8/10

15.9% revenue growth

Free Cash FlowQuality
$1.01B8/10

Generating 1.0B in free cash flow

DIS3 strengths · Avg: 8.3/10
Market CapQuality
$170.94B9/10

Large-cap with strong market position

P/E RatioValuation
14.2x8/10

Attractively priced relative to earnings

Price/BookValuation
1.6x8/10

Reasonable price relative to book value

Areas to Watch

BSX1 concerns · Avg: 4.0/10
P/E RatioValuation
35.1x4/10

Premium valuation, high expectations priced in

DIS4 concerns · Avg: 2.5/10
Altman Z-ScoreHealth
1.914/10

Grey zone — moderate risk

PEG RatioValuation
2.832/10

Expensive relative to growth rate

EPS GrowthGrowth
-4.3%2/10

Earnings declined 4.3%

Free Cash FlowQuality
$-2.28B2/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : BSX

The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.

Bull Case : DIS

The strongest argument for DIS centers on Market Cap, P/E Ratio, Price/Book.

Bear Case : BSX

The primary concerns for BSX are P/E Ratio.

Bear Case : DIS

The primary concerns for DIS are Altman Z-Score, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

BSX profiles as a growth stock while DIS is a value play — different risk/reward profiles.

DIS carries more volatility with a beta of 1.44 — expect wider price swings.

BSX is growing revenue faster at 15.9% — sustainability is the question.

BSX generates stronger free cash flow (1.0B), providing more financial flexibility.

Bottom Line

BSX scores higher overall (63/100 vs 59/100) and 15.9% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Boston Scientific Corp

HEALTHCARE · MEDICAL DEVICES · USA

Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.

Walt Disney Company

COMMUNICATION SERVICES · ENTERTAINMENT · USA

The Walt Disney Company, commonly known as Disney, is an American diversified multinational mass media and entertainment conglomerate headquartered at the Walt Disney Studios complex in Burbank, California.

Visit Website →

Want to dig deeper into these stocks?